mRNA-based prophylactic vaccinesin collaboration with GSK

Addressing infectious diseases

Multivalent Constructs

Influenza vaccine candidates(Modified mRNA)

Partner

FLU SV mRNA

Influenza vaccine candidate(Modified mRNA)

Partner

CV0601 / CV0701

Mono- and bivalent constructs COVID-19 vaccine candidates (Modified mRNA)

Partner

CV0501

COVID-19 vaccine candidate(Modified mRNA)

Partner

Other infectious diseases

Partner

mRNA-based prophylactic vaccines

Addressing infectious diseases

CV7202

Rabies vaccine candidate

Various projects

Rota, malaria, universal influenza

Partner

Ongoing Research – Malaria & Rota – Research

With support from the Bill & Melinda Gates Foundation, research is being conducted to leverage CureVac’s prophylactic vaccine technology to develop mRNA-based vaccines to prevent infectious diseases that disproportionately affect people in the world’s poorest countries.

RNA-based cancer immunotherapies

CVGBM

Multi-epitope mRNA cancer vaccine candidateSurgically resected glioblastoma

Phase 1 study details
Email address for interested patients: glioblastoma.trial@curevac.com

CVGBM is CureVac’s first investigational cancer vaccine based on its proprietary second-generation mRNA backbone. It encodes a single fusion protein comprising eight epitopes derived from tumor-associated antigens (TAA) with relevance in glioblastoma, including HLA class I epitopes presented on HLA A0201 and class II epitopes. The applied epitopes have been previously shown to induce immune responses in glioblastoma patients when administered as peptide vaccines with adjuvants. CVGBM applies unmodified mRNA and is formulated within lipid nanoparticles (LNPs).

CV8102

Non-coding RNA oncology candidateSolid tumors

Off-the-Shelf Cancer Vaccines

Undisclosed

Personalized Cancer Vaccines

Undisclosed

Molecular therapies

Cas9 gene-editing

Partner

Gene-editing – Pre-clinical

CureVac is collaborating with CRISPR Therapeutics to develop novel Cas9 mRNA constructs, which have improved properties for gene editing applications, such as increased potency, decreased duration of expression, and reduced potential for immunogenicity.

For more information about our partnership with CRISPR click here.

Liver Diseases

Ocular diseases

Partner

Therapeutic antibodies

Partner